The Glen Research concept was based on our perception that the research community required a supply of novel reagents which, at first glance, may have seemed of little commercial value to the larger suppliers. We saw these esoteric products as the potential vehicles for the development of novel strategies for use in diagnostics, sequencing, and therapeutics. At the same time, we foresaw a need to provide products for routine oligonucleotide synthesis backed with quality specifications, analytical techniques and certification at the highest level.
The initial Glen Research offering in 1987 contained a complete set of reagents for DNA synthesis for cyanoethyl (CE) phosphoramidite chemistry which then was rapidly gaining acceptance. Modest though this range may have been, it was of major significance due to the Certificates of Analysis which accompanied every product. The analytical techniques and quality criteria used for the evaluation and acceptance of these reagents were to become an industry standard many years later.
This rather routine beginning was soon followed by the products which have become the Glen Research specialty: the largest selection of minor base phosphoramidites available and a potentially bewildering variety of reagents for oligonucleotide modification. To aid researchers in deciphering this array of products and to prompt them as to potential uses, the Glen Research Report was launched. Now published semi-annually as The Glen Report, this unique, valuable and respected newsletter has introduced an astonishing array of novel reagents while elucidating some complex chemical strategies and techniques. Today, Glen Research still offers far and away the widest selection of minor base phosphoramidites, modifiers and reagents for labelling oligonucleotides during the synthesis.
In 1989, Glen Research expanded into the delicate art of RNA synthesis, introducing the set of monomers still respected as the best available for the vast majority of applications. And, in 1990, we launched what was to become the most comprehensive range of products for the synthesis of the nuclease resistant variant 2'-OMe-RNA.
During 1993, Glen Research announced the Sterling line of products for DNA synthesis based on the highest criteria of quality, purity and reproducibility. Sterling grade is the level to which all other suppliers must aspire and which will lead the way to the development of oligonucleotide therapeutics.
As the market for oligonucleotides, modified and unmodified, continues to grow, Glen Research is committed to continuing to introduce novel reagents and techniques while maintaining our existing product mix and high level of customer service.
United States
